Skip to main content
American Conference Institute’s 8th Annual Summit on Biosimilars

American Conference Institute’s 8th Annual Summit on Biosimilars

American Conference Institute’s 8th Annual Summit on Biosimilars

Presented By: American Conference Institute

About the Event

The premier event where industry leaders from both innovator and biosimilar companies discuss the future of biosimilars with regards to regulations, patents, and game-changing legal developments.

With four biosimilars (products interchangeable with FDA-licensed biological products) approved in the U.S. and many more applications currently before the FDA, the business of biosimilars seemed to be in full swing in 2016.  Now, due to a new administration and the potential repeal of the ACA, the future of biosimilars is currently uncertain.

Potential topics to be discussed this year include:

  • The status of the Biologics Price Competition and Innovation Act (BPCIA) cases to date and the future of the Affordable Care Act.
  • Insights into FDA’s current and future initiatives.
  • Overview and analysis of the seven ongoing biosimilar litigations.
  • The flourishing U.S. biosimilars market and evaluating its risk and commercial opportunity
  • Creating biosimilar patent itigation strategies involving both inter-parties review and new U.S. Patent and Trademark Office procedures.
  • Controversies surrounding competition, substitution, and naming in the biosimilars arena.

June 12 - 14, 2017

Monday, June 12, 2017
8:00 AM - 5:30 PM EST

Tuesday, June 13, 2017
8:45 AM - 5:00 PM EST

Wednesday, June 14, 2017
9:00 AM - 5:00 PM EST

InterContinental New York Times Square 
300 W 44th Street 
New York, NY 10036



JAMS Featured Speakers

Hon. Garrett E. Brown, Jr. (Ret.)

Judges Speak: Inside Perspectives on Biosimilar Litigation
Tuesday, June 13, 2017 | 2:30 PM - 3:45 PM EST


Featured People

Hon. Garrett E. Brown, Jr. (Ret.)
  • Antitrust & Competition
  • Banking
  • Bankruptcy
  • Business Commercial
  • Civil Rights
  • Class Action & Mass Tort
  • Construction
  • Employment Law
  • Environmental Law
  • Federal Law
  • Governmental & Public Agency
  • Health Care
  • Insurance
  • Intellectual Property
  • International & Cross-Border
  • Life Sciences
  • Pharmaceuticals & Mass Torts
  • Securities
Scroll to top